Get started
MODERNAMODERNAMODERNA

MODERNA

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

1MRNA chart


Full chart

Key facts today


JP Morgan has maintained an 'Underweight' rating on Moderna (MRNA) and has reduced its price target for the company's shares from $40.00 to $33.00.
Analyze the impactAnalyze the impact

1MRNA upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪11.54 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−8.965 EUR
Net income (FY)
‪−3.44 B‬ EUR
Revenue (FY)
‪3.13 B‬ EUR
Shares float
‪341.66 M‬
Beta (1Y)
0.46

Employees


Employees (FY)
‪5.8 K‬
Change (1Y)
+200 +3.57%
Revenue / Employee (1Y)
‪538.95 K‬ EUR
Net income / Employee (1Y)
‪−593.08 K‬ EUR

About Moderna, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Stéphane Bancel
Website
modernatx.com
Headquarters
Cambridge
Founded
2010
FIGI
BBG01C4Y0B99
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

1MRNA news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where 1MRNA is featured.

See all sparks 


Check out other big names from the same industry as 1MRNA.

Frequently Asked Questions


The current price of 1MRNA is 29.800 EUR — it has decreased by −2.28% in the past 24 hours. Watch MODERNA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange MODERNA stocks are traded under the ticker 1MRNA.
1MRNA stock has fallen by −7.11% compared to the previous week, the month change is a −12.05% fall, over the last year MODERNA has showed a −68.47% decrease.
We've gathered analysts' opinions on MODERNA future price: according to them, 1MRNA price has a max estimate of 195.34 EUR and a min estimate of 23.04 EUR. Watch 1MRNA chart and read a more detailed MODERNA stock forecast: see what analysts think of MODERNA and suggest that you do with its stocks.
1MRNA reached its all-time high on Dec 14, 2022 with the price of 203.000 EUR, and its all-time low was 27.830 EUR and was reached on Mar 4, 2025. View more price dynamics on 1MRNA chart.
See other stocks reaching their highest and lowest prices.
1MRNA stock is 5.14% volatile and has beta coefficient of 0.46. Track MODERNA stock price on the chart and check out the list of the most volatile stocks — is MODERNA there?
Today MODERNA has the market capitalization of ‪11.54 B‬, it has increased by 2.72% over the last week.
Yes, you can track MODERNA financials in yearly and quarterly reports right on TradingView.
MODERNA is going to release the next earnings report on May 1, 2025. Keep track of upcoming events with our Earnings Calendar.
1MRNA earnings for the last quarter are −2.81 EUR per share, whereas the estimation was −2.59 EUR resulting in a −8.57% surprise. The estimated earnings for the next quarter are −2.84 EUR per share. See more details about MODERNA earnings.
MODERNA revenue for the last quarter amounts to ‪933.13 M‬ EUR, despite the estimated figure of ‪910.74 M‬ EUR. In the next quarter, revenue is expected to reach ‪116.42 M‬ EUR.
1MRNA net income for the last quarter is ‪−1.08 B‬ EUR, while the quarter before that showed ‪11.68 M‬ EUR of net income which accounts for ‪−9.37 K‬% change. Track more MODERNA financial stats to get the full picture.
No, 1MRNA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Mar 22, 2025, the company has ‪5.80 K‬ employees. See our rating of the largest employees — is MODERNA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MODERNA EBITDA is ‪−3.63 B‬ EUR, and current EBITDA margin is −116.07%. See more stats in MODERNA financial statements.
Like other stocks, 1MRNA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MODERNA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MODERNA technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MODERNA stock shows the sell signal. See more of MODERNA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.